AI-driven QSAR and PBK models trained on human data to predict ADMET profiles before any lab work begins.

QSAR ensemble evaluates compound structures against human clinical outcomes. PBK simulation predicts dose-response in human organ compartments.

Advanced 3D human tissue culture systems are used to determine the toxicity risks of new drug candidates.

Our hepatic, renal, cardiac, intestinal, neural, and lung organoids are derived from biobanked human iPSC under full ethical consent.

Azunic doesn’t stop at the data. We coordinate your regulatory submission for IND/CTN, translating our findings into the package regulatory reviewers expect.

Complete regulatory-ready submissions aligned with FDA Modernization Act 2.0, ICH M7/S7A/S7B, and OECD Test Guidelines.

High-throughput compound triage in weeks. Kill or advance candidates before investing in full development.

From SMILES input to go/no-go in under 3 weeks. Tiered screening layers in silico flagging with targeted organoid confirmation.

Mechanistic toxicology studies on target organs: liver, kidney, cardiac, CNS.

Multi-organ mechanistic study maps toxicity thresholds, reversibility, and pathway mechanisms for IND filing.

Azunic handles IND/CTN submission coordination end to end, so your team can move from tox results to filing without juggling vendors or reformatting data.

Azunic handles IND/CTN submission coordination end to end, so your team can move from tox results to filing without juggling vendors or reformatting data.